DexCom boosted its 2026 non-GAAP operating margin guidance to 23%-23.5% after reporting strong Q1 revenue growth and product momentum. Management credited expanded coverage for type 2 non-insulin ...

Q1 2026 Management view DexCom reported Q1 momentum tied to coverage expansion, product rollout, and operational execution, with President, CEO & Director Jacob Leach highlighting “first quarter ...

DexCom Inc (DXCM) reports a robust 15% revenue increase, driven by international demand and strategic product launches, despite challenges in the US market.

Medical device maker Dexcom on Thursday reiterated its full-year revenue forecast after beating Wall Street estimates for ...

Add Yahoo as a preferred source to see more of our stories on Google. The Dexcom G7 Continuous Glucose Monitoring (CGM) System, shown here with an iPhone and an Apple Watch. (Courtesy of Dexcom) This ...

The CGM provides real-time glucose readings for 15.5 days. “As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” ...

DexCom (NASDAQ: DXCM) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the ...

Dexcom G7 CGMs contain a complex electronic assembly within a wearable package that stands up to the rigors of everyday ...

New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Ontario residents eligible for ODB and ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over ...